✦ LIBER ✦

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

✍ Scribed by Maurie Markman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of bevacizumab to weekly paclit

✍ David M. O'Malley; Debra L. Richardson; Patrick S. Rheaume; Ritu Salani; Eric L. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Response to letter to the editor in resp

✍ David M. O'Malley 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Sustained progression-free survival with

✍ J.D. Hurt; D.L. Richardson; L.G. Seamon; J.F. Fowler; L.J. Copeland; D.E. Cohn; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 233 KB